Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the operating margin high or low?
The operating margin of -288.98% is 53% above its 5-year average of -609.13%, near the high end of its 5-year range (-1550.05%–71.06%).
58.09% above its 12-month average of -689.51%.
Reported quarterly operating margin; no daily interpolation. Q2 FY2026 (2026-06-30): -1550.05%.
OPERATING MARGIN
-288.98%
OPERATING MARGIN AVG TTM
-689.51%
OPERATING MARGIN AVG 3Y
-899.79%
OPERATING MARGIN AVG 5Y
-609.13%
OPERATING MARGIN AVG 10Y
N/A
OPERATING MARGIN AVG 15Y
N/A
OPERATING MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+58.09%
CURRENT VS 3Y AVG
+67.88%
CURRENT VS 5Y AVG
+52.56%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 494 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
AbCellera Biologics Inc.
Market Cap
$4.21B
Operating Margin
-288.98%
TTM Avg
-689.51%
3Y Avg
-899.79%
5Y Avg
-609.13%
Market Cap
$4.34B
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$4.49B
Operating Margin
21.39%
TTM Avg
12.04%
3Y Avg
0.21%
5Y Avg
0.61%
Market Cap
$4.50B
Operating Margin
-34.31%
TTM Avg
-42.52%
3Y Avg
-56.23%
5Y Avg
-56.23%
Market Cap
$4.78B
Operating Margin
-20.62%
TTM Avg
-55.73%
3Y Avg
-88.20%
5Y Avg
-107.26%
Market Cap
$3.62B
Operating Margin
-72.84%
TTM Avg
-2371.95%
3Y Avg
-1360.37%
5Y Avg
-967.05%
Market Cap
$4.81B
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | OPERATING MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $4.21B | -288.98% | -689.51% | -899.79% | -609.13% |
| Edgewise Therapeutics, Inc. (EWTX)vs › | $4.34B | 0.00% | 0.00% | 0.00% | 0.00% |
| ICU Medical, Inc. (ICUI)vs › | $4.03B | 5.04% | 3.30% | 1.43% | 3.80% |
| Indivior Pharmaceuticals Inc (INDV)vs › | $4.49B | 21.39% | 12.04% | 0.21% | 0.61% |
| Heartflow, Inc. Common Stock (HTFL)vs › | $4.50B | -34.31% | -42.52% | -56.23% | -56.23% |
| Adaptive Biotechnologies Corporation (ADPT)vs › | $4.78B | -20.62% | -55.73% | -88.20% | -107.26% |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.62B | -72.84% | -2371.95% | -1360.37% | -967.05% |
| CareDx, Inc (CDNA)vs › | $3.61B | -0.92% | 2.81% | -22.73% | -18.78% |
| Definium Therapeutics, Inc. (DFTX)vs › | $4.81B | 0.00% | 0.00% | 0.00% | 0.00% |
| Celcuity Inc. (CELC)vs › | $3.59B | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
61.6%
Operating Margin
-289.0%
Operating Margin = Operating Income / Revenue
Operating margin is the percentage of revenue remaining after operating expenses, reflecting operating efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | OPERATING MARGIN |
|---|---|
| 2026-06-30 | -1550.05% |
| 2026-03-31 | -691.75% |
| 2025-12-31 | -63.72% |
| 2025-09-30 | -851.79% |
| 2025-06-30 | -290.24% |
| 2025-03-31 | -1479.57% |
| 2024-12-31 | -1440.69% |
| 2024-09-30 | -1439.42% |
| 2024-06-30 | -1276.17% |
| 2024-03-31 | -551.48% |
| 2023-12-31 | -719.61% |
| 2023-09-30 | -831.79% |
| 2023-06-30 | -511.03% |
| 2023-03-31 | -532.10% |
| 2022-12-31 | -175.34% |
| 2022-09-30 | 37.22% |
| 2022-06-30 | -18.29% |
| 2022-03-31 | 71.06% |
| 2021-12-31 | 58.53% |
| 2021-09-30 | -510.09% |
| 2021-06-30 | -25.44% |
| 2021-03-31 | 77.97% |
| 2020-12-31 | 77.33% |
| 2020-09-30 | -18.88% |
| 2020-06-30 | -7.61% |
| 2020-03-31 | -45.57% |
| 2019-12-31 | -61.70% |
| 2019-09-30 | -20.74% |
| 2019-06-30 | -28.75% |
| 2019-03-31 | -28.75% |
